Amitkumar Nitinkuma Mehta MD
Hematologic Oncology
Lymphoma Program, Assistant Professor, Hematology & Oncology University of Alabama at Birmingham
1720 2nd Ave S Np2540tBirmingham, AL 35294
Fax+1 205-934-1608
Overview of Dr. Mehta
I am currently assistant professor and associate scientist at the University of Alabama at Birmingham Comprehensive Cancer Center (UABCCC). I am board certified in Internal Medicine, Hematology and Oncology. My focus of interest is LYMPHOMA (Hodgkin lymphoma, Non Hodgkin lymphoma-T cell and B cell lymphomas). I specialize in treatments all types of lymphoma in my clinic. I am also involved in lymphoma related research which includes genomic and proteomic (gene and protein related) studies in various kinds of lymphomas. As a clinical investigator I am also part of many clinical trials as principal investigator or sub investigator. Many new promising targeted and immunologic treatment for lymphomas are being developed at UABCCC which patients of lymphoma can benefit. My passion is to develop targeted and immunologic therapies in lymphomas with less toxicities and more effectiveness.
UABCCC lymphoma program is comprehensive program involving all specialists (medical oncology, surgical oncology, radiation oncology, survivorship and integrative medicine) and great nurses.
Apart from lymphomas, I also see patients with blood cancers (Leukemia, Myelodysplastic syndrome, low blood counts, CLL, Langerhans cell histiocytosis, Rosai Dorfman's syndrome etc) and blood related disorders (benign hematology like PTGC, ITP, hemolytic anemia, iron deficiency anemia).
http://www.uab.edu/medicine/hemonc/faculty/amitkumar-mehta-md
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Providence HospitalResidency, Internal Medicine, 2008 - 2011
Baroda Medical CollegeClass of 2002
Certifications & Licensure
AL State Medical License 2011 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Chief Resident Providence Hospital, 2011
Clinical Trials
- A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Oct 15
- Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas Start of enrollment: 2014 Dec 01
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Start of enrollment: 2015 May 01
- Join now to see all
Publications & Presentations
PubMed
- Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.Sunandini Sharma, Roshia Ali, Alyssa Bouska, Dylan Jochum, Meghana Kesireddy
Nature Communications. 2025-11-05 - 1 citationsPhase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston
Clinical Lymphoma, Myeloma & Leukemia. 2025-11-01 - Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.Pamela B Allen, Subir Goyal, Swaminathan Iyer, Sai Talluru, Auris Huen
Journal of the American Academy of Dermatology. 2025-09-29
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Amitkumar Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Adult Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Other
- Patient-Centered Care in Chronic Lymphocytic LeukemiaUma M. Borate, MD, MS; Amitkumar Mehta, MD; Thomas W. Butler, MD; Richard Taylor, DNP, CRNP; Myeisha D. Hutchinson; Ellen Frederick, RN, BSN, OCN, Medscape Oncology education
http://www.medscape.org/viewarticle/842755
6/15/2015
Press Mentions
Three Factors to Consider in Relapsed/Refractory Follicular Lymphoma CareSeptember 9th, 2025- UAB Helps College Cheerleader Tackle CancerNovember 16th, 2022
Expensive Gilead, Novartis Cancer Therapies Losing Patients to Experimental TreatmentsJuly 30th, 2019- Join now to see all
Grant Support
- Young Investigator Award-2014Conquer Cancer Foundation-American Society of Clinical OncologyPresent
Professional Memberships
- Member
- Member
- Member
- American Association of Cancer Research (AACR)Member
Other Languages
- Hindi, Gujarati
External Links
- UAB Medicinehttp://www.uab.edu/medicine/hemonc/faculty/amitkumar-mehta-md
- LinkedInhttps://www.linkedin.com/pub/amitkumar-mehta/52/98b/199
- Podcast-Oncotherapyhttp://www.oncotherapynetwork.com/podcasts/daratumumab-may-exert-indirect-effects-multiple-myeloma
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
